TY - JOUR
T1 - Microbiota intestinal e função dos probióticos na síndrome do intestino irritável
T2 - Uma revisão
AU - Moraes-Filho, Joaquim Prado
AU - Quigley, Eamonn M.M.
N1 - Publisher Copyright:
© 2015, IBEPEGE - Inst. Bras. Estudos Pesquisas Gastroent. All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015/10
Y1 - 2015/10
N2 - Irritable bowel syndrome is a common, chronic relapsing gastrointestinal disorder that affects 7%–22% of the population worldwide. According to Rome III Criteria, the disorder is defined by the coexistence of abdominal discomfort or pain associated with an alteration in bowel habits. Its pathophysiology is not completely understood but, in addition to some important abnormalities, the disturbed intestinal microbiota has also been described supported by several strands of evidence. The treatment of irritable bowel syndrome is based upon several therapeutic approaches but few have been successful or without adverse events and more recently the gut microbiota and the use of probiotics have emerged as a factor to be considered. Probiotics are live micro-organisms which when consumed in adequate amounts confer a health benefit to the host, such as Lactic bacteria among others. An important scientific rationale has emerged for the use of probiotics in irritable bowel syndrome, although the data regarding different species are still limited. Not all probiotics are beneficial: it is important to select the specific strain which should be supported by good evidence base. The mechanisms of action of probiotics are described and the main strains are quoted.
AB - Irritable bowel syndrome is a common, chronic relapsing gastrointestinal disorder that affects 7%–22% of the population worldwide. According to Rome III Criteria, the disorder is defined by the coexistence of abdominal discomfort or pain associated with an alteration in bowel habits. Its pathophysiology is not completely understood but, in addition to some important abnormalities, the disturbed intestinal microbiota has also been described supported by several strands of evidence. The treatment of irritable bowel syndrome is based upon several therapeutic approaches but few have been successful or without adverse events and more recently the gut microbiota and the use of probiotics have emerged as a factor to be considered. Probiotics are live micro-organisms which when consumed in adequate amounts confer a health benefit to the host, such as Lactic bacteria among others. An important scientific rationale has emerged for the use of probiotics in irritable bowel syndrome, although the data regarding different species are still limited. Not all probiotics are beneficial: it is important to select the specific strain which should be supported by good evidence base. The mechanisms of action of probiotics are described and the main strains are quoted.
KW - Irritable bowel syndrome
KW - Microbiota
KW - Probiotics
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=84956944165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956944165&partnerID=8YFLogxK
U2 - 10.1590/S0004-28032015000400015
DO - 10.1590/S0004-28032015000400015
M3 - Review article
C2 - 26840477
AN - SCOPUS:84956944165
VL - 52
SP - 331
EP - 338
JO - Arquivos de Gastroenterologia
JF - Arquivos de Gastroenterologia
SN - 0004-2803
IS - 4
ER -